Eli Lilly (NYSE:LLY) announced today that it plans to execute price reductions of 70% for its most commonly prescribed insulins.
Indianapolis-based Lilly also plans to expand its Insulin Value Program. This caps patient out-of-pocket costs at $35 or less per month.
The company said it took these actions to “help Americans” in a “complex healthcare system” that can keep them from receiving affordable insulin.
Get the full story at our sister site, Drug Delivery Business News.